Empowering specificity of AML immunotherapies by HSC engineering |
Boston Children’s Hospital / Pietro Genovese |
Catalyst Grants |
2023 |
Massachusetts |
Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Elucidating the Roles of Aneuploidy in Down Syndrome-Associated Leukemia |
Boston Children’s Hospital / Chun-Chin Chen, PhD |
Young Investigator Grants |
2023 |
Massachusetts |
Ectopic Neuroligin Signaling in Pediatric Glioblastoma |
University of Utah / Alex Shcheglovitov, PhD |
Innovation Grants |
2023 |
Utah |
Targeting Oncogenic N-MYC Complexes in High-Risk Neuroblastoma |
The Regents of the University of California San Francisco / Bo Qiu, MD/PhD |
Young Investigator Grants |
2023 |
California |
Stapled Oncolytic Peptides for Treatment-Resistant Pediatric Leukemias |
Dana-Farber Cancer Institute / Loren Walensky, MD, PhD |
Innovation Grants |
2023 |
Massachusetts |
Mutagenesis and disease progression in RUNX1 mutant blood stem cells is caused by inflammation-induced hyperactive signaling and supraphysiological mitochondrial ROS |
St. Jude Children’s Research Hospital / Dirk Loeffler, PhD |
RUNX1 Early Career Investigator Grants |
2023 |
Tennessee |
Desmoplastic Small Round Cell Tumors: Investigation of its Pathogenesis and Development of Novel Therapies |
Memorial Sloan-Kettering Cancer Center / Andrea Ventura, MD, PhD |
Innovation Grants |
2023 |
New York |
A Genomics Driven Pluripotent Stem Cell Model of Infant Lymphoblastic Leukemia |
Children's Mercy Hospital Kansas City / Meagan Vacek, DO |
Catalyst Grants |
2023 |
Missouri |